Figure 1.

Duration on study treatment for all patients who are treated with at least one dose of study treatment. The cases highlighted in green are response evaluable patients by RECIST v1.1 and those in red were non-evaluable patients. MOB2-009 highlighted with * was the only evaluable patient who achieved stable disease as the best tumor response and all other evaluable patients had progressive disease. MOB2-004 highlighted with ^# was on study treatment for 147 days with a CA-19-9 response and clinical stability, however, the patient was inevaluable for radiological response evaluation due to severe contrast allergy.